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Abstract
Alveolar macrophages (AM) are critical to the homeostasis of the inflammatory environment in the lung. Differential
expression of surface markers classifies macrophages to either classically (M1) or alternatively activated (M2). We
investigated the phenotype of human alveolar macrophages (AM) in adults living in two different geographical
locations: UK and Malawi. We show that the majority of AM express high levels of M1 and M2 markers simultaneously,
with the M1/M2 phenotype being stable in individuals from different geographical locations. The combined M1/M2
features confer to AM a hybrid phenotype, which does not fit the classic macrophage classification. This hybrid
phenotype may confer to alveolar macrophages an ability to quickly switch between M1 or M2 associated functions
allowing for appropriate responses to stimuli and tissue environment.
Introduction
The healthy human alveoli are dominated by alveolar
macrophages (AM) [1]. These cells play a critical role in
regulating immune responses [2] and maintaining
homeostasis in the lung [1, 3]. Their plasticity to adapt
to changes in their microenvironment is fundamental in
retaining the lung health [4]. Macrophages have been
categorised as “polarised” towards either M1 (proinflam-
matory, mediating resistance to pathogens), or M2 mode
(anti-inflammatory, promoting tissue remodelling) [5].
This categorisation is derived from murine models, and
from in vitro polarisation of human macrophages using
a combination of cytokines. However, whether AM
polarisation in steady state fits the traditional M1/M2 di-
chotomy is still not well understood. We therefore inves-
tigated human AM polarisation in steady state, and
ascertained the stability of the phenotype in two geo-
graphical locations and following in vivo exposure to
bacterial and viral stimuli.
Methods
Briefly, in the UK, healthy, non-smoking participants
aged 18–50 years were recruited from an ongoing
study of the Experimental human pneumococcal chal-
lenge (EHPC) model [6]. A subset of 25 participants,
16 individuals who had become colonized (carriage +)
with Streptococcus pneumoniae, and 9 who had not
(carriage –) underwent research bronchoscopy at 4 to
7 weeks after the bacterial challenge. Alveolar macro-
phages were obtained from bronchoalveolar lavage
(BAL), as described previously [7]. In Queen Elizabeth
Central Hospital (QECH), Malawi, BAL samples [8]
were obtained from selected asymptomatic adults
(≥18 yrs), comprising ten HIV-1-uninfected healthy
controls and ten age-matched ART-naïve HIV-1-
infected individuals. We excluded participants with
clinical evidence of active disease or recent history of
severe respiratory illness.
Flow cytometry-based immunophenotyping was
used to characterise AM phenotype obtained from
BAL fluid. The expressional levels of key surface
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Results
Human alveolar macrophages simultaneously express M1
and M2 markers in steady state
Data from the two human cohorts from distinct geograph-
ical locations, UK (Additional file 1 Table S1) and Malawi
(Additional file 1 Table S2), were collected independently
and their comparison revealed a similar pattern of surface
marker expression by AM. In both cohorts, the majority
of AM were characterised as CD206hiCD86hi. M1-like
phenotype (CD206loCD86hi) and M2-like phenotype
(CD206hiCD86lo) subsets represented a small proportion
(less than 1%) of the total AM population (Fig. 1a and c).
In addition, the CD206hiCD86hi subset expressed greater
levels of the M2 marker, CD163, compared to the M1 and
M2 subpopulations (Fig. 1b and d). UK samples were
further analysed for additional M1 markers (CD80, CD64)
and an activation marker (HLADR). In these, the
CD206hiCD86hi subset expressed the highest levels of
CD80, CD64 and HLADR expression in comparison to
the other AM subsets (Fig. 1e-g).
Colonization with pneumococcus does not alter
the AM phenotype, whereas chronic HIV infection
is associated with a lower expression of CD163 on
CD206loCD86hi AM
We have previously shown that live intranasal pneumo-
coccal challenge alters the alveolar environment by in-
creasing the levels of pneumococcal-specific memory
CD4+ Th17 cells in the human lung [9], and that HIV
infection disrupts the alveolar cytokine microenvironment
[10]. We therefore investigated whether in vivo exposure
to intranasal pneumococcal challenge or HIV
infection polarise the AM phenotype. We compared
experimentally pneumococcal-colonized individuals
with non-colonized individuals, as well as, asymptom-
atic ART-naïve HIV-infected adults with age-matched
HIV-uninfected healthy individuals. We found no
difference in M1 or M2-like phenotype between indi-
viduals who became colonized following inoculation
with S. pneumoniae compared with those who cleared
the bacteria (Fig. 1a). Specifically, the expression of
CD163 (Fig. 1b), CD80, CD64 and HLADR measured
in the four AM subsets remain at the same levels
between these groups (Fig. 1e-g).
Interestingly, in the Malawian population, AM sub-
sets from HIV-infected individuals followed the same
pattern of subdivision described in healthy volunteers.
No difference was found in the proportion of the in-
vestigated subsets between the ART-naïve HIV-
infected adults and HIV-uninfected healthy individuals
(Fig. 1c). However, the expression of CD163 was sig-
nificantly reduced in the CD206loCD86hi subset in
HIV-infected individuals (p = 0.0147) (Fig. 1d).
Discussion
In our study, we compared the polarisation of AM iso-
lated from human volunteers from distinct geographical
locations, UK and Malawi. We report that in healthy hu-
man pulmonary mucosa, AM adopt a hybrid phenotype,
which shares features of both M1 (CD80, CD86, CD64)
and M2 (CD206 and CD163) polarized macrophages.
The same phenotype has been previously reported on
the decidual macrophages (resident macrophages of the
uterine lining), which exhibit characteristics of both pro-
inflammatory and tolerogenic macrophages [11].
We also found that nasal pneumococcal colonization,
even though it alters CD4+ T cell responses in the
alveoli [9], does not alter the expression of key M1 and
M2 polarization markers on the surface of AM. This
leads to the speculation that a nasal pneumococcal
exposure episode is either incompetent to modulate AM
polarization or its effect is transient and quickly
irreversible due to macrophages high plasticity [4]. By
contrast, chronic HIV infection did affect the expression
of CD163 on the M1-like AM subset (CD206loCD86hi),
with a lower expression of CD163 observed in HIV-
infected individuals than HIV-uninfected controls. This
finding is intriguing and may be due to active HIV infec-
tion of this alveolar macrophage subset [12] which has
been shown to strongly repress CD163 expression on
infected-macrophages [13]. Furthermore, CD163 is shed
during activation as soluble CD163 (sCD163) [14] and
this might in part explain the reduction of CD163 on
the surface M1-like AM in HIV-infected individuals.
However, even with in vivo exposure to pneumococci
or HIV, the CD206hiCD86hi AM subset remained the
major population, and this ascertains the stability of
this phenotype.
Our data provides strong evidence suggesting that not
all macrophages fall into M1 and M2 subsets. The major
AM population in steady state expresses a duo M1/M2
phenotype. This phenotype is present in individuals from
two distinct geographical location and is stable even
after exposure to stimuli known to alter the alveolar en-
vironment. This is consistent with recent call for a re-
think of the M1/M2 macrophage paradigm [5]. It is
possible that the lack of stark polarisation is helpful in
maintaining a healthy balance between immune toler-
ance and protective immunity in the alveolar space.
However, whether other tissue macrophages, beyond de-
cidual and alveolar macrophages, exhibit similar pheno-
types in vivo warrants further investigation.
Conclusion
The clear majority of alveolar macrophages combine M1
and M2 features in steady state, a phenotype that may
allow brisk and adaptive responsiveness to multiple
elements in the local milieu.






Fig. 1 Comparison of human alveolar macrophage phenotype between UK and Malawi healthy adults (a) Percentages of AM subsets gated for
CD206 and CD86 (UK cohort, n = 9 for grey bars and n = 16 for black bars) and the (b) the degree of CD163 expression in each of the subsets.
The data shows that CD206hiCD86hi subset occupies the highest proportion and expresses the highest levels of CD163 when compared with the
other three. c-d The same pattern is observed on the AM derived from the healthy Malawian individuals (grey bars, n = 10). The effect of
pneumococcal colonization and HIV infection on AM polarisation. a-b AM subsets are compared between non-colonized (carriage -) and colonized
group (carriage +) post experimental nasal pneumococcal inoculation. There is no alteration of AM phenotype associated with nasal pneumococcal
colonization. CD206hiCD86hi is the dominant subset with the highest CD163 expression amongst the rest (p < 0.0001 when compared
with CD206loCD86hi or CD206hiCD86lo. c AM subsets are compared between HIV-uninfected healthy adults (n = 10) and HIV-infected individuals
(n = 10). AM collected from HIV-infected individuals follows the same pattern with healthy HIV-uninfected individuals when gated for CD206 and
CD86. d CD206hiCD86hi is the dominant subset with the highest CD163 expression amongst the rest (p < 0.002 when compared with CD206loCD86hi
or CD206hiCD86lo in both HIV-uninfected and HIV-infected individuals. However, the HIV infection regresses the expression of CD163 in the CD206loCD86hi
subset. e-g Levels of CD80, CD64 and HLADR expression respectively between carriage negative and carriage positive individuals. There is no significant
difference on levels of CD80, CD64 and HLADR expression mediated by nasopharynx pneumococcal colonization. Within-group comparisons used
Wilcoxon tests, and between-cohort comparisons used Mann-Whitney U test
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Additional file 1: Table S1. Demographics of the EHPC study
participants- UK. Table S2. Demographics of study participants – Malawi.
Table S3. Summary of the panel composition at the UK site (no shading) and
Malawi site (grey shading). Fig. S1. Gating strategy used to identify human
alveolar macrophages in the UK Cohort. Fig. S2. Gating strategy used to
identify human alveolar macrophages in the Malawi Cohort. (DOCX 681 kb)
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